Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its product pipeline includes JTX-2011 (ICOS), JTX-4014 (PD-1), the Lead Macrophage Program, Macrophage Targeting, T Reg, B Cells, and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

NEW YORK--(BUSINESS WIRE)--Jounce Media has recognized Yahoo Backstage via the Yahoo DSP as the "largest MFA-free supply source on the open Web.".

Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source

Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights

Jounce Therapeutics Announces Closing of Tender Offer

Catalyst Pharmaceuticals

KalVista Pharma

Larimar Therapeutics Inc

Nektar Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

5 Stocks to Buy as the Drug Industry Rebounds in 2023

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable contingent value right is fair to Jounce shareholders.

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

Redx Pharma said it has been notified that Jounce Therapeutics (NASDAQ:JNCE) is pulling out of their merger announced in February in favour of a rival cash offer from Concentra Biosciences. A cooperation agreement between Redx and Nasdaq-listed Jounce has also been scrapped.

Redx Pharma 'disappointed' as Jounce pulls out of merger

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

Agenus

Hub Cyber Security Ltd

Kinross Gold

Oatly

Protalix Biotherapeutics

QualTek Services

Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now: 7 To Watch Before Next Week

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Energy Vault Holdings

Comscore Inc.

Solid Power

thredUP

Insiders are buying these penny stocks but are they worth the risk? The post 5 Top Penny Stocks To Buy In March According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy In March According To Insiders

Fintel reports that Tang Capital Partners has filed a 13D form with the SEC disclosing ownership of 5.30MM shares of Jounce Therapeutics Inc (JNCE).

Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics

Jounce Therapeutics (NASDAQ: JNCE ) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences. That acquisition offer has Concentra Biosciences seeking to acquire JNCE stock for $1.80 per share in cash.

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

SVB Financial Group

Shares of Jounce Therapeutics Inc. JNCE, -6.09% bounced 6.6% in premarket trading Monday, after the immunotherapy company said only about $2.6 million, or 1.4% of its total cash and cash equivalents was in an operating account at SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, which was shut down last week. Jounce, which had $189.5 million in total cash and cash equivalents as of Dec. 31, said it also holds a $1.3 million letter of credit at SBV.

Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account

NEW YORK , Feb. 27, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Jounce Therapeutics, Inc. (NASDAQ: JNCE), relating to its proposed merger with Redx Pharma. Click here for more information: https://www.monteverdelaw.com/case/jounce-therapeutics-inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Jounce Therapeutics, Inc. - JNCE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Jounce Therapeutics, Inc. (the “Company”) (NasdaqGS: JNCE) with Redx Pharma Plc. Under the terms of the proposed transaction, Jounce shareholders will end up owning approximately 37% of the share capital of the combined group.

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE

Terran Orbital Corp

Vascular Biogenics

Use these tips to make money with penny stocks when day trading The post Maximizing Returns With Penny Stocks: Day Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Maximizing Returns With Penny Stocks: Day Trading

Jounce Therapeutics (NASDAQ: JNCE ) stock is on the rise Thursday after the company revealed merger plans with Redx Pharma . Jounce Therapeutics and Redx Pharma will undergo a merger with an all-stock transaction fueling it.

Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Redx Pharma is fair to Jounce shareholders. Halper Sadeh encourages Jounce shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

JNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Jounce Therapeutics, Inc. Is Fair to Shareholders

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease

Redx and Jounce Announce Recommended Business Combination

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the Company cannot pursue on its own and will be seeking business development opportunities for both programs.

Jounce Therapeutics Announces Restructuring

Jounce has recently announced that it has sold its entire rights to immunotherapy candidate GS-1181 to Gilead for $67 million. I expect the biotech company to now have around $170 million cash, with a market cap of about $55 million.

Jounce: Gilead's GS-1811 Buyout Allows A Further Bounce

Ambev

Cenntro Inc

Innovative Eyewear Inc

Use these tips to read penny stocks market news The post How to Read Penny Stocks News and Use it to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Read Penny Stocks News and Use it to Profit

Gilead Sciences

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

News for Jounce Therapeutics Stock (JNCE)